3 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Severe Hemophilia A: new trials by email Literature Review of Severe Hemophilia A trials Research Report on Severe Hemophilia A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. MARSTACIMAB - Severe Hemophilia A | Phase 1 | Recruiting | Pfizer | 15 | 2025-05-13 | 2026-10-15 |
| To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A GS1191-0445 injection - Severe Hemophilia A | Phase 1 / Phase 2 | Active not recruiting | Gritgen Therapeutics Co., Ltd. | 7 | 2023-07-10 | 2026-05-06 |
| A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection ADVATE, FRSW117 - Severe Hemophilia A | Phase 1 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 13 | 2021-06-22 | 2023-09-08 |
| Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A OCTA101 - Severe Hemophilia A | Phase 1 / Phase 2 | Terminated | Octapharma | 36 | 2019-07-03 | 2026-10-15 |
| Pharmacokinetics of rFVIIIFc at Two Vial Strengths rFVIIIFc - Severe Hemophilia A | Phase 1 | Completed | Bioverativ Therapeutics Inc. | 19 | 2014-03-01 | 2020-12-19 |
| Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A rFVIIIFc - Severe Hemophilia A | Phase 1 | Completed | Bioverativ Therapeutics Inc. | 16 | 2009-12-01 | 2020-12-19 |
Hemophilia A (6) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Hemic and Lymphatic Diseases (6) · Blood Coagulation Disorders (5) · Blood Coagulation Disorders, Inherited (5) · Coagulation Protein Disorders (5) · Genetic Diseases, Inborn (5) · Hematologic Diseases (5) · Hemorrhagic Disorders (5)
factor VIII-Fc fusion protein (2) · Factor VIII (1) · Injections (1) · marstacimab (1)
Bioverativ Therapeutics Inc. (2) · Gritgen Therapeutics Co., Ltd. (1) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (1) · Octapharma (1) · Pfizer (1)
United States (3) · China (2) · Australia (1) · Bulgaria (1) · Hong Kong (1) · India (1) · Israel (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Renchi Yang, PhD (1)